Children's Oncology Group's 2023 blueprint for research: Liver tumors

O’Neill, Allison F.; Meyers, Rebecka L.; Katzenstein, Howard M.; Geller, James I.; Tiao, Greg; López‐Terrada, Dolores; Malogolowkin, Marcio H.

doi:10.1002/pbc.30576

Cited by 3 publications

(2 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 Both entities are exceedingly rare in children and young adults and are predicted, in aggregate, to occur with a frequency of approximately 100–150 cases/year in the United States. 5 Outcomes for patients who present with upfront, resectable disease are excellent with an approximate 85% 5-year overall survival. 6 The majority of patients, however, present with advanced disease precluding resection and resulting in dismal outcomes.…”

Section: Introductionmentioning

confidence: 99%

Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series

O’Neill,

Church,

Feraco

et al. 2024

eBioMedicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series

O’Neill,

Church,

Feraco

et al. 2024

eBioMedicine

View full text Add to dashboard Cite

“…The combination of surgery and NACT has significantly improved postoperative survival in highrisk children with HB (1). Currently, the pretreatment extent of disease (PRETEXT)/the post-treatment extent of disease (POSTTEXT) staging based on imaging is widely used in prognosis prediction and treatment decision-making of HB patients (7)(8)(9). The PRETEXT staging is determined by imaging at diagnosis and the POSTTEXT staging is determined after neoadjuvant chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy

Zheng,

Ye,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionInflammation is closely associated with tumor development and patient prognosis. The objective of this study is to assess the prognostic value of the preoperative inflammatory indexes in pediatric hepatoblastoma patients who receive neoadjuvant chemotherapy.Methods:A retrospective analysis was performed on clinical and pathological data of 199 hepatoblastoma patients who underwent hepatectomy with preoperative neoadjuvant chemotherapy from January 2015 to June 2020. The receiver operating characteristic curve was used to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) in predicting OS and EFS. Patients were grouped based on optimal cutoff values of preoperative inflammatory indexes. Survival rates were calculated using the Kaplan-Meier method, and survival outcomes were compared between groups using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to identify independent prognostic factors, and a nomogram was constructed using R software to predict the probability of OS.ResultsThe receiver operating characteristic curve showed prognostic value for OS, not EFS, in preoperative inflammatory indexes. Patients were categorized into low/high groups: SII ≤ 266.70/higher, NLR ≤ 1.24/higher, PLR ≤ 85.25/higher, and SIRI ≤ 0.72/higher. High NLR, PLR, SII, and SIRI groups had significantly lower 5-year OS than their low counterparts (all p-value < 0.05). The Cox analysis identified four independent prognostic factors: SIRI (HR=2.997, 95% CI: 1.119-8.031), microvascular invasion (HR=2.556, 95% CI: 1.14-5.73), the post-treatment extent of disease (POSTTEXT) staging (IV vs. I: HR=244.204, 95% CI:11.306-5274.556), and alpha-fetoprotein (>100 ng/ml: HR=0.11, 95% CI: 0.032-0.381) for hepatoblastoma patients with neoadjuvant chemotherapy. High SIRI group had more patients with adverse NLR, SII, and POSTTEXT III (all p-value < 0.05). Independent prognostic factors led to an OS nomogram with a concordance index of 0.85 (95% CI: 0.78-0.91, p-value = 1.43e-27) and the calibration curve showed a good fit between the prediction curve and the true curve.ConclusionsSIRI is an independent prognostic factor of hepatoblastoma patients receiving neoadjuvant chemotherapy. The OS nomogram based on SIRI, POSTTEXT staging, MiVI, and AFP can be used to assess the prognosis of those patients.

show abstract

Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials

Metts,

Aye,

Crane

et al. 2024

Cancer

View full text Add to dashboard Cite

Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large‐scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment‐related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.

show abstract

Children's Oncology Group's 2023 blueprint for research: Liver tumors

Cited by 3 publications

References 103 publications

Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series

Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy

Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials

Contact Info

Product

Resources

About